Bell Investment Advisors’s Vir Biotechnology VIR Stock Holding History

Bell Investment Advisors’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27	Closed	-$155	–	1952
2025 Q3	$155	Hold	27	–	–	﹤0.01%	1854
2025 Q2	$137	Hold	27	–	–	﹤0.01%	1858
2025 Q1	$175	Hold	27	–	–	﹤0.01%	1872
2024 Q4	$199	Hold	27	–	–	﹤0.01%	1872
2024 Q3	$203	Hold	27	–	–	﹤0.01%	1857
2024 Q2	$241	Hold	27	–	–	﹤0.01%	1914
2024 Q1	$274	Hold	27	–	–	﹤0.01%	1891
2023 Q4	$272	Hold	27	–	–	﹤0.01%	1890
2023 Q3	$253	Sell	27 -48	-64%	-$685	﹤0.01%	1894
2023 Q2	$1.84K	Sell	75 -23	-23%	-$578	﹤0.01%	1343
2023 Q1	$2.28K	Hold	98	–	–	﹤0.01%	1196
2022 Q4	$2.48K	Buy	98 +45	+85%	+$1.1K	﹤0.01%	1176
2022 Q3	$1K	Buy	53 +9	+20%	+$229	﹤0.01%	1622
2022 Q2	$1K	Buy	+44	New	+$1.03K	﹤0.01%	1645
2021 Q4	$1K	Buy	24 +12	+100%	+$470	﹤0.01%	1651
2021 Q3	$1K	Buy	+12	New	+$520	﹤0.01%	1601

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GSK plc London $602M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Bell Investment Advisors's VIR Position: Q4 2025 in Review

Bell Investment Advisors sold out of Vir Biotechnology (VIR) in Q4 2025, closing a stake of 27 shares — an estimated $155 sold.

Bell Investment Advisors first reported a position in VIR in Q3 2021 and held it in 16 quarters. The position peaked at $2.48K in Q4 2022. 218 funds tracked by Wall St. Rank hold VIR as of Q4 2025.

Bell Investment Advisors reported no remaining Vir Biotechnology position as of Q4 2025 after selling out during the quarter.
Bell Investment Advisors sold 27 Vir Biotechnology shares in Q4 2025, an estimated $155.
Bell Investment Advisors first reported a position in Vir Biotechnology in Q3 2021 and held it in 16 quarters.
Bell Investment Advisors's Vir Biotechnology position peaked at $2.48K in Q4 2022.
218 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2025.

Based on Bell Investment Advisors's 13F filing for Q4 2025, filed 24 Feb 2026.